Trial Profile
A retrospective, cohort study assessing the epidemiological, clinical, and radiological characteristics of treatment used DMARD, anti-TNFα, anti-IL6, glucocorticoids in patients with Rheumatoid arthritis and Diffuse interstitial lung disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Baricitinib (Primary) ; Glucocorticoids (Primary) ; Interleukin 6 inhibitors (Primary) ; Methotrexate (Primary) ; Rituximab (Primary)
- Indications Interstitial lung diseases; Rheumatoid arthritis; Sjogren's syndrome
- Focus Therapeutic Use
- 23 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism